CALLY Index, Frailty and SOFA-2 for Mortality Prediction in Geriatric ICU Patients (CALLY-FS)

May 6, 2026 updated by: tugba yesilyurt dogu, Istanbul University - Cerrahpasa

Prognostic Value of CALLY Index, Frailty and SOFA-2 Score for Mortality in Geriatric Intensive Care Patients: A Prospective Cohort Study

This study aims to evaluate the prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index, Clinical Frailty Scale (CFS), and SOFA-2 score in predicting mortality among geriatric intensive care unit (ICU) patients.

The primary outcome is ICU mortality. Secondary outcomes include 28-day mortality, ICU length of stay, duration of mechanical ventilation, need for renal replacement therapy, and vasopressor requirement.

The study also investigates whether the combined use of these parameters improves predictive performance compared to conventional scoring systems such as APACHE II.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a single-center, prospective observational cohort study including patients aged ≥65 years admitted to the intensive care unit.

Demographic characteristics, comorbidities, frailty status (Clinical Frailty Scale), and severity scores (SOFA-2, APACHE II) will be recorded. Laboratory parameters including C-reactive protein, albumin, and lymphocyte count will be used to calculate the CALLY index within the first 24 hours of ICU admission.

Patients will be followed for ICU mortality and 28-day mortality. Additional outcomes include ICU and hospital length of stay, duration of mechanical ventilation, vasopressor requirement, and need for renal replacement therapy.

Statistical analyses will include logistic regression and receiver operating characteristic (ROC) curve analysis to evaluate the predictive performance of each parameter and their combined use.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Geriatric patients (aged ≥65 years) admitted to the intensive care unit.

Description

Inclusion Criteria:

  • Age ≥65 years
  • Admission to the intensive care unit
  • Availability of required clinical and laboratory data within the first 24 hours of ICU admission

Exclusion Criteria:

  • Death within the first 24 hours after ICU admission
  • Missing key clinical or laboratory data
  • Terminal malignancy receiving palliative care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Geriatric ICU patients
Geriatric patients (aged ≥65 years) admitted to the intensive care unit will be included as a single observational cohort. All participants will be evaluated for CALLY index, frailty status, and SOFA-2 score within the first 24 hours of ICU admission.
Other: observational study
No intervention is applied.This is an observational study in which patients receive standart clinical care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ICU Mortality
Time Frame: From ICU admission until ICU discharge or death, assessed up to 28 days
All-cause mortality occurring during the intensive care unit stay.
From ICU admission until ICU discharge or death, assessed up to 28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
28-day Mortality
Time Frame: 28 days
All-cause mortality within 28 days after ICU admission.
28 days
ICU Length of Stay
Time Frame: From ICU admission until ICU discharge or death, assessed up to 28 days
Duration of stay in the intensive care unit, measured in days.
From ICU admission until ICU discharge or death, assessed up to 28 days
Hospital Length of Stay
Time Frame: From hospital admission until hospital discharge or death, assessed up to 28 days
Total length of hospital stay, measured in days.
From hospital admission until hospital discharge or death, assessed up to 28 days
Duration of Mechanical Ventilation
Time Frame: From initiation of invasive mechanical ventilation until discontinuation, assessed up to 28 days
Total duration of invasive mechanical ventilation, measured in days.
From initiation of invasive mechanical ventilation until discontinuation, assessed up to 28 days
Vasopressor Requirement
Time Frame: From ICU admission until ICU discharge or death, assessed up to 28 days
Requirement for vasopressor support at any time during ICU stay.
From ICU admission until ICU discharge or death, assessed up to 28 days
Renal Replacement Therapy Requirement
Time Frame: From ICU admission until ICU discharge or death, assessed up to 28 days
Requirement for renal replacement therapy (RRT) during ICU stay.
From ICU admission until ICU discharge or death, assessed up to 28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul University - Cerrahpasa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

July 10, 2026

Study Registration Dates

First Submitted

April 30, 2026

First Submitted That Met QC Criteria

May 6, 2026

First Posted (Actual)

May 12, 2026

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 6, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KAEK/04.02.2026.82

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly available due to institutional and ethical restrictions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

Clinical Trials on observational study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe